Epratuzumab Phase IIb Study Shows Positive Effect in Moderate to Severe S.L.E.
Tuesday, November 9, 2010
ATLANTA – UCB and U.S. based partner Immunomedics Inc. announced that results from the phase IIb study, EMBLEM™, showed that certain doses of epratuzumab were associated with a meaningful and statistically significant* reduction in disease activity in adult patients with moderate to severe active SLE.
On the go?
Text INFO to 50555 and opt-in to receive breaking news about lupus on your mobile phone.
Message and Data Rates May Apply. Text STOP to 50555 to STOP. Text HELP to 50555 for HELP. Full Terms